[1] Cornistein W,Mora A,Orellana N, et al. Candida:epidemiology and risk factors for non-albicans species[J]. Enferm Infecc Microbiol Clin,2013,31(6):380-384.
[2] Silva S,Negri M,Henriques M, et al. Candida glabrata,Candida parapsilosis and Candida tropicalis:biology, epidemiology,pathogenicity and antifungal resistance[J]. FEMS Microbiol Rev,2012,36(2):288-305.
[3] Clinical and Laboratory Standards Institute.Performance Standards for Antimicrobial Susceptibility Testing.Twtentieth informational supplement[S].M1O0-S20.CLSI,2010.
[4] Liu W,Tan J,Sun J et al.Invasive candidiasis in intensive care units in China:in vitro antifungal susceptibility in the China-SCAN study[J].J Antimicrob Chemother,2014,69(1):162-167.
[5] Wang H,Xiao M,Chen SC,et al.In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET)study[J].J Clin Microbiol,2012,50(12):3952-3959.
[6] 范欣,徐英春.侵袭性热带念珠菌感染流行病学及药物敏感性[J].中国真菌学杂志,2014,9(6):368-372.
[7] Kothari A,Sagar V.Epideniology of Candida bloodstream infections in a tertiary care institute in India[J].Indian J Med Microbiol,2009,27(2):171-172.
[8] Silva NC,Nery JM,Dias AL. Aspartic proteinases of Candida spp.:role in patnogenicity and antifungal resistance[J]. Mycoses,2014,57(1):1-11.
[9] Yang SP,Chen YY,Hsu HS,et al.A risk factor analysis of healthcare-associated fungal infections in an intensive care unit:a retrospective cohort study[J].BMC Infect Dis,2013,13:10.
[10] Cisterna R,Ezpeleta G,Telleria O,et al.Nstionwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain[J].J Clin Microbiol,2010,48(11):4200-4206.
[11] Nucci M,Queiroz-Telles F,Tobon AM,et al.Epidemiology of opportunistic fungal infections in Latin America[J].Clin Infect Dis,2010,51(5):561-570.
[12] 王昊,吴大玮,韩辉,等.白念珠菌与非白念珠菌血流感染危险因素、抗菌药物应用及预后比较[J].中华传染病学杂志,2014,32(8):474-478.